Investment Rating - The report assigns a "Buy" rating for the company, marking its first coverage [2][4]. Core Insights - The company has shown significant revenue and profit growth in Q3 2024, with a year-over-year revenue increase of 19.02% and a net profit increase of 45.05% [3][4]. - The company has received multiple product approvals, enhancing its product portfolio and demonstrating confidence through an employee stock ownership plan [4]. - The projected revenues for 2024, 2025, and 2026 are estimated at 1.217 billion yuan, 1.406 billion yuan, and 1.608 billion yuan respectively, with corresponding net profits of 247 million yuan, 290 million yuan, and 337 million yuan [4][6]. Financial Performance Summary - For the first three quarters of 2024, the company reported revenues of 854 million yuan, a 16.14% increase year-over-year, and a net profit of 183 million yuan, up 20.80% year-over-year [3][4]. - In Q3 2024, the gross margin was reported at 41.66%, a decrease of 2.47 percentage points year-over-year, while the net profit margin improved by 3.85 percentage points to 21.98% [4]. - The company’s total market capitalization is approximately 6.577 billion yuan, with a circulating market value of about 6.555 billion yuan [4]. Valuation Metrics - The report provides a forecast for the company's earnings per share (EPS) to be 1.09 yuan in 2024, 1.28 yuan in 2025, and 1.49 yuan in 2026, with a projected price-to-earnings (P/E) ratio of 26.58X for 2024 [6][8]. - The return on equity (ROE) is expected to improve from 11% in 2023 to 13% by 2026 [8].

Investment Rating - The investment rating for the company is "Buy" (maintained) [1][2] Core Views - The company reported a revenue of 854 million yuan for Q3 2024, representing a year-on-year increase of 16.14%, and a net profit attributable to shareholders of 183 million yuan, up 20.8% year-on-year [1] - The company has a diverse product range, including 11 types of products and 23 specifications, with human albumin and immunoglobulin being the main revenue sources, accounting for over 70% of total revenue [1] - The acquisition by China National Pharmaceutical Group is expected to bring new opportunities and resources, enhancing the company's competitiveness and innovation capabilities in the biopharmaceutical sector [1] Financial Performance Summary - For 2023, the company achieved a revenue of 1,049 million yuan, with a projected revenue of 1,149 million yuan for 2024, reflecting a growth of 9.6% [3][5] - The net profit attributable to shareholders for 2023 was 219 million yuan, with an expected increase to 236 million yuan in 2024, indicating a growth of 7.8% [3][5] - The gross margin for 2024 is projected to be 42.0%, an increase from 41.3% in 2023 [3][5] Cash Flow and Balance Sheet Summary - The operating cash flow for 2023 was 398 million yuan, with a significant drop expected to 25 million yuan in 2024 [4] - Total assets are projected to grow from 2,877 million yuan in 2023 to 3,115 million yuan in 2024 [4] - The company’s total liabilities are expected to remain stable at around 842 million yuan in 2024 [4]

Financial Performance - Revenue for Q3 2024 reached ¥331,198,949.54, an increase of 19.02% year-over-year[2] - Net profit attributable to shareholders was ¥72,838,708.50, up 45.05% compared to the same period last year[2] - Basic earnings per share for the period was ¥0.3212, reflecting a 45.08% increase year-over-year[2] - Total operating revenue for the third quarter reached ¥854,101,695.51, an increase of 16.1% compared to ¥735,431,674.00 in the same period last year[13] - Net profit attributable to shareholders of the parent company was ¥182,700,428.15, up 20.8% from ¥151,241,017.19 year-on-year[14] - Operating profit for the quarter was ¥217,276,259.92, representing a 21.6% increase from ¥178,634,888.00 in the previous year[14] - Basic and diluted earnings per share were both ¥0.8056, compared to ¥0.6668 in the same period last year, marking a 20.8% increase[14] Assets and Liabilities - Total assets at the end of the period amounted to ¥3,171,207,936.49, a growth of 10.23% from the end of the previous year[2] - Total assets amounted to ¥3,171,207,936.49, compared to ¥2,876,778,757.84 in the previous year, reflecting a growth of 10.2%[12] - Total liabilities amounted to approximately RMB 998.40 million, up from RMB 831.14 million, reflecting an increase of about 20.1%[11] - The company has a total equity of approximately RMB 2.17 billion, up from RMB 2.05 billion, indicating a growth of about 5.9%[11] Cash Flow - Cash flow from operating activities for the year-to-date was ¥100,979,444.84, showing a decline of 53.22% year-over-year[2] - Cash flow from operating activities generated a net amount of ¥100,979,444.84, down 53.2% from ¥215,850,869.32 in the same quarter last year[15] - The net cash flow from financing activities was CNY 106,122,041.96, compared to a negative cash flow of CNY -93,042,457.83 in the previous period[16] - Cash and cash equivalents at the end of the period totaled CNY 255,807,762.34, an increase from CNY 192,239,644.28 in the previous period[16] - The net increase in cash and cash equivalents was CNY 4,362,080.83, compared to a decrease of CNY -102,252,417.27 in the previous period[16] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 10,061[6] - The largest shareholder, Shenzhen Guangming District State-owned Assets Supervision and Administration Bureau, holds 65.25% of the shares[6] Accounts Receivable and Inventory - The company reported a significant increase in accounts receivable by 97.34% due to revenue growth[5] - Accounts receivable increased significantly to approximately RMB 109.33 million from RMB 55.40 million, representing a growth of about 96.9%[10] - Inventory rose to approximately RMB 781.35 million, compared to RMB 672.98 million, marking an increase of around 16.1%[10] Research and Development - The company is actively involved in research and development, focusing on new product innovations and market expansion strategies[10] - Research and development expenses were ¥38,106,155.61, a decrease of 24.4% from ¥50,435,388.95 in the previous year[13] Future Outlook - Future outlook includes plans for further market expansion and potential mergers and acquisitions to enhance growth[10] Financial Expenses - Financial expenses increased by 71.99% to ¥14,204,485.37, primarily due to rising interest costs[5] Audit Information - The company did not undergo an audit for the third quarter report[17]

证券代码:002880 证券简称:卫光生物 公告编号:2024-033 深圳市卫光生物制品股份有限公司 关于变更职工代表监事的公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性 陈述或重大遗漏。 深圳市卫光生物制品股份有限公司（以下简称公司）监事会于近日收到职工代 表监事吴恩应先生的书面辞职报告，因工作变动，吴恩应先生辞去职工代表监事职务， 辞职后不再担任公司任何职务。截至本公告披露日，吴恩应先生未直接持有公司股票， 通过参与公司第三期员工持股计划间接持有公司股份。吴恩应先生任职期间勤勉尽责， 公司及监事会对吴恩应先生在任职期间所做出的贡献表示衷心感谢! 为保障监事会正常运作，根据《公司法》及《公司章程》等的有关规定，公司 于 2024 年 9 月 4 日召开职工代表大会，选举黎占露先生(简历详见附件)为公司第三届 监事会职工代表监事，任期自职工代表大会选举通过之日起至公司第三届监事会届满 之日止。 特此公告。 深圳市卫光生物制品股份有限公司监事会 2024 年 9 月 6 日 附件：黎占露先生简历 黎占露，男，中国国籍，无境外永久居留权，1981 年出生，研究生学历，中山 ...

卫光生物（ [Table_StockNameRptType] 002880） 公司点评 | --- | --- | --- | |-----------------------------------------------------------------------------------------------------------------------|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

Financial Performance - The company's operating revenue for the first half of 2024 was approximately ¥522.90 million, representing a 14.38% increase compared to ¥457.17 million in the same period last year[10]. - The net profit attributable to shareholders for the same period was approximately ¥109.86 million, an increase of 8.75% from ¥101.03 million year-on-year[10]. - Basic and diluted earnings per share for the first half of 2024 were both ¥0.4844, marking an 8.76% increase from ¥0.4454 in the same period last year[10]. - The total revenue for the reporting period reached ¥522,902,745.97, representing a year-on-year increase of 14.38% from ¥457,166,651.70[30]. - Blood products accounted for ¥458,068,846.60, or 87.60% of total revenue, with a year-on-year growth of 4.63%[30]. - The total profit for the first half of 2024 was CNY 131,335,735.48, compared to CNY 119,872,406.65 in the first half of 2023, representing an increase of about 9.9%[92]. - The company's total comprehensive income attributable to shareholders for the first half of 2024 was CNY 109,727,347.83, compared to CNY 100,887,995.32 in the first half of 2023, reflecting an increase of approximately 8.2%[93]. Cash Flow and Investments - The net cash flow from operating activities decreased significantly by 65.80%, amounting to approximately ¥76.27 million compared to ¥222.99 million in the previous year[10]. - The company reported a net investment loss of ¥120,874.33, which accounted for -0.09% of total profit[32]. - The net cash flow from investing activities was -¥152,040,777.06, worsening from -¥111,530,780.07 in the first half of 2023[98]. - Cash inflow from financing activities significantly increased to ¥215,363,296.33, compared to ¥61,666,806.14 in the same period last year, marking a growth of 248.5%[98]. - The company has increased its cash flow from financing activities significantly, reporting CNY 129.52 million compared to a negative CNY 50.04 million in the previous year[28]. Assets and Liabilities - Total assets as of June 30, 2024, reached approximately ¥3.08 billion, reflecting a 7.01% increase from ¥2.88 billion at the end of the previous year[10]. - The net assets attributable to shareholders increased by 2.66%, totaling approximately ¥2.07 billion compared to ¥2.01 billion at the end of the previous year[10]. - Total liabilities amounted to CNY 978,398,634.44, an increase from CNY 831,139,505.24, representing a growth of approximately 17.7%[89]. - The company's total equity reached CNY 2,100,006,478.20, up from CNY 2,045,639,252.60, reflecting a growth of approximately 2.7%[89]. Research and Development - The company has established eight major research and innovation platforms, including the "Guangdong Province Protein (Peptide) Engineering Research and Development Center" and the "Shenzhen Blood Products Engineering Research and Development Center" to enhance its R&D capabilities[24]. - The company’s R&D investment increased by 11.09% to CNY 20.87 million from CNY 18.78 million, reflecting a commitment to enhancing research capabilities[28]. - The company is focusing on rare diseases and major infectious diseases in its R&D efforts, with key projects including human plasminogen and new intravenous human immunoglobulin[24]. - The company emphasizes innovation and talent development, implementing a scientific research incentive mechanism to stimulate innovation vitality[20]. Market and Product Development - The company focuses on expanding its market presence by enhancing sales efforts in key hospitals and teaching hospitals, optimizing professional academic promotion, and new product promotion strategies[20]. - The company obtained the drug registration certificate for prothrombin complex, further enriching its product line and enhancing the comprehensive utilization rate of raw plasma[20]. - The company has developed a diverse product range including human albumin, immunoglobulin, and coagulation factors, with a total of 11 varieties and 23 specifications[16]. - The company is actively exploring new biological medicine businesses, including vaccines and gene-engineered products, alongside its core blood products[16]. Risk Management - The company emphasizes the importance of risk awareness regarding future plans and strategies, as outlined in the report[1]. - The company faces risks related to insufficient raw plasma supply due to stricter regulations on establishing new plasma collection stations[43]. - The company plans to enhance its research and development capabilities to mitigate risks associated with new product development, including optimizing management mechanisms and improving personnel incentives[44]. - The company is addressing potential safety risks in blood products by continuously improving quality management systems and production processes[45]. Environmental and Social Responsibility - The company has obtained environmental impact assessment approvals for its blood product production line expansion project and has a valid pollution discharge permit until December 4, 2027[54]. - The company has implemented a distributed photovoltaic power generation facility to increase the use of green energy and reduce carbon emissions[58]. - The company engaged in social welfare activities, with nearly 150 registered volunteers and over 100 volunteer service instances during the reporting period[60]. - The company invested approximately CNY 240,000 in poverty alleviation efforts, including CNY 140,000 for purchasing agricultural products from supported areas and CNY 100,000 in donations[61]. Shareholder Information - The company held two shareholder meetings during the reporting period, with participation rates of 73.73% and 72.74% respectively[48]. - The company does not plan to distribute cash dividends or issue bonus shares for the half-year period[50]. - The total number of ordinary shareholders at the end of the reporting period was 9,600[78]. - The largest shareholder, the State-owned Assets Supervision and Administration Commission of Shenzhen, holds 65.25% of the shares, totaling 147,987,000 shares[79].

| 非经营性资 | 资金占用 | 占用方与上 | 上市公司核算 | 2024 年期初 | 2024 年 1-6 占用累计发生 | 月 | 2024 年 | 1-6 | 2024 年 | 1-6 | 2024 年 1- | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 金占用 | 方名称 | 市公司的关 | | 占用资金余 | | | 月占用资金的 | | 月偿还累计 | | 月期末占 6 | 占用形成原因 | 占用性质 | | | | 联关系 | 的会计科目 | 额 | 金额（不含利 | | 利息(如有) | | 发生金额 | | 用资金余额 | | | | | | | | | 息） | | | | | | | | | | 现大股东及 | | | | | | | | | | | | | | | 其附属企业 | | | | | | | | | | | | | | | 小计 | | | | | | | | | | | | | | | 前大股东及 | | | | | | | | ...

深圳市卫光生物制品股份有限公司（以下简称公司）董事会于近日收到公司 副总经理许强先生提交的退休离任报告。许强先生因退休离任，不再担任公司副 总经理职务。截至本公告日，许强先生未直接持有公司股份，通过参与公司第三 期员工持股计划间接持有公司股份。根据《深圳证券交易所上市公司自律监管指 引第 1 号——主板上市公司规范运作》等的相关规定，许强先生的离任报告自送 达公司董事会之日起生效，其离任不会影响公司相关工作的正常开展。 证券代码:002880 证券简称:卫光生物 公告编号:2024-031 深圳市卫光生物制品股份有限公司 关于高级管理人员退休离任的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 许强先生在公司任职期间勤勉尽责，公司及董事会对许强先生在任职期间为 公司发展所做出的贡献表示衷心感谢！ 特此公告。 深圳市卫光生物制品股份有限公司董事会 2024 年 8 月 22 日 ...

Investment Rating - The investment rating for the company is "Buy" [1][3]. Core Views - The entry of China National Pharmaceutical Group (Sinopharm) as a major shareholder is expected to enhance the company's resources and support, boosting its competitiveness and innovation in the biopharmaceutical sector [1][14]. - The company has shown continuous revenue growth, with revenue increasing from 623 million yuan in 2017 to 1.048 billion yuan in 2023, representing a CAGR of 9.05% [1][18]. - The company’s blood products account for approximately 80% of total revenue, with significant growth in the sales of human albumin and immunoglobulin [1][18]. Summary by Sections Company Overview - Established in 1985, the company focuses on blood products and has become a leading player in the domestic market with a high plasma utilization rate and a strong R&D capability [1][9]. - The company’s main products include human albumin, immunoglobulin, and coagulation factors, with a total of 11 varieties and 23 specifications [1][12]. Financial Performance - Revenue for 2023 was 1.049 billion yuan, with a year-on-year growth of 57% [3][5]. - The net profit attributable to the parent company for 2023 was 219 million yuan, reflecting an 86.1% increase year-on-year [5][19]. - The gross profit margin for 2023 was 41.3%, with a net profit margin of 20.75% [5][19]. Market and Industry Trends - The blood products market in China is experiencing rapid growth, with the market size increasing from 28.3 billion yuan in 2018 to 51.2 billion yuan in 2022, representing a CAGR of 15.98% [24]. - The demand for blood products is expected to continue growing due to increasing healthcare awareness and an aging population [24][25]. Future Outlook - Revenue projections for 2024-2026 are estimated at 1.149 billion yuan, 1.308 billion yuan, and 1.478 billion yuan, respectively, with corresponding net profits of 236 million yuan, 267 million yuan, and 304 million yuan [3][5]. - The company is actively pursuing new product development, with several projects in the pipeline expected to positively impact future performance [2][3].

证券代码:002880 证券简称:卫光生物 公告编号:2024-030 深圳市卫光生物制品股份有限公司 2023 年度权益分派实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性 陈述或重大遗漏。 深圳市卫光生物制品股份有限公司（以下简称公司） 2023 年度权益分派方案已经 2024 年 5 月 17 日召开的 2023 年度股东大会审议通过，现将权益分派事宜公告如下： 一、股东大会审议通过利润分配方案情况 1.公司 2023 年度利润分配方案为：以公司截至 2023 年 12 月 31 日的总股本 226,800,000 股为基数，每 10 股派发现金红利 2 元（含税），拟派发现金红利总额为 45,360,000 元，不送红股，不以公积金转增股本。 2.本权益分派预案从披露至实施期间公司股本总额未发生变化，本次实施分配的 预案与股东大会审议通过的分配预案一致。 3.本次利润分配方案按照分配总额不变的原则实施。 4.本次实施分配方案距离股东大会审议通过的时间未超过两个月。 二、权益分派方案 本公司 2023 年度权益分派方案为：以公司现有总股本 226,800,000 ...